Bioxytran is a company focused on developing treatments for stroke and Ischemia. More than 140,000 deaths occur each year due to stroke. Sign up to learn more about BioxyTran and join the fight, because when it comes to stroke, every second counts.


With hypoxia, seconds make the difference between life and death. We are committed to bridging those moments through the structure of co-polymers. Based on Dr. David Platt's groundbreaking research in carbohydrate chemistry, Bioxytran, Inc is developing treatments for stroke and many other medical situations related to hypoxic conditions.

Learn More

Learn about Stroke
and Ischemia

In the United States, about 795,000 people suffer a stroke each year. Someone has a stroke every 40 seconds, and every 4 minutes someone dies from stroke. There are more than 140,000 deaths each year from stroke.  

Learn More


The key is BioXyTran's two workhorses: BXT-25 and BXT-252. Both drugs are designed to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid.

Learn More

Latest articles

Bioxytran’s Tissue Oxygenation Therapy Breaking the Stroke Paradigm
Jun 15, 2019

Bioxytran Inc. (BIXT) has a novel drug for stroke patients that can restore the supply of oxygen to the brain. Strokes effects over 900,000 people per year and the indirect costs of stroke due to disability and special services are over $22 billion annually.

The Pressure is On: Following New Blood Pressure Guidelines Could Prevent Death Among Stroke Survivors
Jun 2, 2019

As of last November, the American College of Cardiology and American Heart Association has updated their guidelines on what constitutes high blood pressure—high blood pressure is now defined as 130/80 compared to the previous 140/90.

Mothers-To-Be: Due Date Soon? Look Out for Infections
Jun 2, 2019

New research shows that infections could trigger a ​stroke in pregnant women during childbirth. Although maternal strokes are rare---only about 30of every 100,000 pregnancies---the fatality rate is extremely high. Stroke is one of the major causes of maternal death in the United States and has been a topic of growing concern among doctors and researchers alike.

see all

Lorem Ipsum

Ola Soderquist
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC).
Elena Chekhova
Chief Scientist
Elena Chekhova received her Ph.D in Process Systems Engineering at MIT; Elena has over 10 years of experience in the life sciences industry Most recently she founded Biotine Consulting, a life science consultancy providing business development and project management services to life science companies in the US and internationally.
David Platt
CEO & Chairman
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials.


Learn more about the team from BioxyTran


Learn more about BioxyTran investors and S1 Stocks


Join the conversation as we discuss Bioxytran's use-cases, development progress, and more.